federal_register: 2017-26725

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2017-26725 Product Name Placement, Size, and Prominence in Promotional Labeling and Advertisements; Guidance for Industry; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Product Name Placement, Size, and Prominence in Promotional Labeling and Advertisements." The guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for human prescription drugs, including prescription biological products, and for animal prescription drugs. This guidance finalizes the revised draft guidance issued on November 20, 2013 ("Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling"). FDA is also announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA). 2017-12-12 2017 12 https://www.federalregister.gov/documents/2017/12/12/2017-26725/product-name-placement-size-and-prominence-in-promotional-labeling-and-advertisements-guidance-for https://www.govinfo.gov/content/pkg/FR-2017-12-12/pdf/2017-26725.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Product Name Placement, Size, and Prominence in Promotional Labeling and Advertisements." The guidance clarifies the requirements for...

Links from other tables